The study was led by a team of researchers in the Netherlands and involved 2,239 patients treated at two tertiary medical centers in Amsterdam between Dec. 31, 2018 and Jan. 6, 2021. Researchers found hospitalized patients taking the proton pump inhibitors had a nearly 50 percent higher chance of colonization of extended-spectrum beta-lactamase- or carbapenemase-producing Enterobacterales. The risk was slightly higher for hospitalized patients who took proton pump inhibitors twice a day.
While colonization doesn’t always lead to illness, it increases the risk of infection.
“These findings emphasize the judicious use of PPIs,” researchers said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
